Related Experiment Video

Updated: Aug 9, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Clinical implications of EGFR expression in the development and progression of solid tumors: focus on non-small cell

David S Ettinger1

  • 1The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21213-1000, USA. ettinda@jhmi.edu

The Oncologist
|April 15, 2006
PubMed

Insights

Dysregulation of the epidermal growth factor receptor (EGFR) pathway fuels cancer. EGFR-targeted therapies, including monoclonal antibodies and tyrosine kinase inhibitors, show promise for treating solid tumors like lung cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Aberrant signaling of the epidermal growth factor receptor (EGFR) pathway is implicated in various malignancies.
  • EGFR plays a crucial role in cell proliferation, survival, and migration, making it a key target in cancer therapy.

Purpose of the Study:

  • To provide a critical update on the current status of novel epidermal growth factor receptor (EGFR)-targeted therapeutics.
  • To review the efficacy of monoclonal antibodies (mAbs) and small-molecule tyrosine kinase inhibitors (TKIs) in treating solid tumors.

Main Methods:

  • Literature review of recent clinical trials and research on EGFR-targeted therapies.
  • Analysis of data on the clinical outcomes of monoclonal antibodies and tyrosine kinase inhibitors.

Main Results:

  • Both EGFR-targeted monoclonal antibodies (mAbs) and small-molecule tyrosine kinase inhibitors (TKIs) have demonstrated significant efficacy.
  • These agents show promise as monotherapies and in combination with chemotherapy and radiotherapy for various solid tumors, notably non-small cell lung cancer.

Conclusions:

  • EGFR-targeted therapies represent a significant advancement in cancer treatment, offering improved outcomes for patients with EGFR-driven malignancies.
  • Continued research and development of these novel therapeutics are crucial for optimizing cancer care.

More Related Videos

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...